Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Papilledema]

S Mishima

    No to Shinkei = Brain and Nerve
    |May 1, 1971
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.

    ESMO gastrointestinal oncology·2026
    Same author

    Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer.

    ESMO gastrointestinal oncology·2026
    Same author

    Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience.

    ESMO gastrointestinal oncology·2026
    Same author

    Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.

    ESMO gastrointestinal oncology·2026
    Same author

    Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: a single-institution experience.

    ESMO gastrointestinal oncology·2026
    Same author

    E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

    ESMO open·2025